Previous Article | Next Article ![]()
J. Virol., Aug 1997, 6037-6043, Vol 71, No. 8
S Lee, K Peden, DS Dimitrov, CC Broder, J Manischewitz, G Denisova, JM Gershoni and H Golding
The entry of human immunodeficiency virus type 1 (HIV-1) into cells is
initiated by binding of the viral glycoprotein gp120-gp41 to its cellular
receptor CD4. The gp120-CD4 complex formed at the cell surface undergoes
conformational changes that may allow its association with an additional
membrane component(s) and the eventual formation of the fusion complex.
These conformational rearrangements are accompanied by immunological
changes manifested by altered reactivity with monoclonal antibodies
specific for the individual components and presentation of new epitopes
unique to the postbinding complex. In order to analyze the structure and
function of the gp120-CD4 complex, monoclonal antibodies were generated
from splenocytes of BALB/c mice immunized with soluble CD4-gp120 (IIIB)
molecules (J. M. Gershoni, G. Denisova, D. Raviv, N. I. Smorodinsky, and D.
Buyaner, FASEB J. 7:1185-1187 1993). One of those monoclonal antibodies,
CG10, was found to be strictly complex specific. Here we demonstrate that
this monoclonal antibody can significantly enhance the fusion of CD4+ cells
with effector cells expressing multiple HIV-1 envelopes. Both
T-cell-line-tropic and macrophage-tropic envelope-mediated cell fusion were
enhanced, albeit at different optimal doses. Furthermore, infection of HeLa
CD4+ (MAGI) cells by HIV-1 LAI, ELI1, and ELI2 strains was increased two-
to fourfold in the presence of CG10 monoclonal antibodies, suggesting an
effect on viral entry. These findings indicate the existence of a novel,
conserved CD4-gp120 intermediate structure that plays an important role in
HIV-1 cell fusion.
Copyright © 1997, American Society for Microbiology
Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody
Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|